Loading…
Hosted by Jeff Trickett · 🇺🇸 US · EN · 17 episodes
Established thought leaders with verified media credentials.
Dr. Jeff Trickett is a neuroscientist, biotech strategist, and author. He hosts Innovating Tomorrow’s Medicine, a podcast highlighting the people and ideas reshaping the future of healthcare. He created the show to go beyond the headlines with honest conversations from biotech founders, researchers, clinicians and investors who are turning bold ideas into real-world impact. His goal is to discover the strategies they use, the insights behind their success and breakthroughs that will define the future of medicine; while challenging the way we think about health, science, and progress.
Jeff Trickett hosts Innovating Tomorrow's Medicine, a science show with 17 episodes published.
What if we could silence disease-causing proteins not by targeting the protein itself, but by preventing its mRNA from ever being translated—using small-molecule drugs? In this episode, David Weitz, Co-founder, President
What if we could stop disease-causing proteins before they're even made—using small molecules to target their mRNA? David Weitz, CEO of Syrna Therapeutics, is pioneering exactly that: 3D structure-guided drug discovery f
What if you could know before a clinical trial which patients will respond? Not after Phase 2 fails. Not after spending $50M. Before you even start. In this episode, Pilgrim Jackson, CEO of Yatiri Bio, shares how his com
What if you could know before enrolling a single patient which ones will actually respond to treatment? Pilgrim Jackson, CEO of Yatiri Bio, is using proteomics to predict treatment response in AML and ovarian cancer with
What if we could help millions quit smoking with a naturally derived compound that's been used for decades—but never brought to the U.S. market until now? In this episode, Rick Stewart, CEO of Achieve Life Sciences, shar
What if a naturally derived compound used for decades overseas could finally transform smoking cessation in the U.S.? Rick Stewart, CEO of Achieve Life Sciences, just received FDA acceptance for cytisinicline's NDA—a maj
What if the key to biotech success isn't just science and strategy—but self-awareness and spiritual practice? In this episode, Dr. Sheila Gujrathi—biotech entrepreneur, executive, and drug developer with over 25 years of
What if the key to biotech success isn't just science and strategy—but self-awareness and spiritual practice? Dr. Sheila Gujrathi—who led the development of Orencia® and Nulojix®—shares insights from her Amazon bestselli
What if we could bring the power of precision medicine to more cancer patients, faster—using AI to match patients with the right treatments at the right time? In this episode, Rick Fultz, CEO of Acurion, shares how his c
What if AI could match cancer patients with the right treatments faster—bringing precision medicine to more people who need it? Rick Fultz, CEO of Acurion, is using artificial intelligence to transform how we select canc
What if we could use gene editing to treat Duchenne Muscular Dystrophy—not just manage symptoms, but address the underlying genetic cause in a scalable, precise way? In this episode, Dr. Courtney Young, CEO of MyoGene Bi
What if gene editing could treat Duchenne Muscular Dystrophy at its genetic root—not just manage symptoms? Dr. Courtney Young, CEO of MyoGene Bio, is using CRISPR to address the underlying cause of Duchenne in a scalable
What if we could destroy cancer cells using a completely novel payload—one that doesn't rely on traditional chemotherapy or even antibody-drug conjugates, but instead uses lytic peptides to obliterate tumors? In this epi
What if we could destroy cancer cells using a completely novel payload that doesn't rely on traditional chemotherapy or even antibody-drug conjugates? Dr. Stanley Lewis, CEO of A28 Therapeutics, is pioneering lytic pepti
What if we could transform the treatment landscape for rheumatologic diseases by taking bold, innovative approaches that go beyond incremental improvements? In this episode, Dr. James Mackay, CEO of Crystalys Therapeutic
What does it take to launch a biotech company with bold, innovative approaches to rheumatologic diseases? Dr. James Mackay, CEO of Crystalys Therapeutics, is bringing next-generation science and strategic leadership to p
What does it take to transform bold ideas into real-world treatments that save lives? Welcome to Innovating Tomorrow's Medicine, a podcast that goes beyond the headlines to explore the strategies, insights, and breakthro
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Innovating Tomorrow's Medicine has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their science audience.
Innovating Tomorrow's Medicine is hosted by Jeff Trickett. The show is categorised under science (life) and has published 17 episodes.
Innovating Tomorrow's Medicine has published 17 episodes.
Innovating Tomorrow's Medicine regularly covers science, life. It sits in the science category, with a life focus.
Innovating Tomorrow's Medicine is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
Innovating Tomorrow's Medicine hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of Innovating Tomorrow's Medicine average 26 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates Innovating Tomorrow's Medicine's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched yesterday.